Companies › Vera Therapeutics
1 active drug program in 3 registered trials: 2 Phase 2, 1 Phase 3; Genitourinary; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Atacicept Tumor necrosis factor ligand superfamily member 13B inhibitor; Tumor necrosis factor ligand superfamily member 13 inhibitor | TNFSF13B, TNFSF13 | Phase 3 | IgA Nephropathy; IgA Nephropathy (IgAN); pMN | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07020923 | Atacicept | Phase 2 | IgA Nephropathy (IgAN) | Genitourinary | Sep 2027 |
| NCT06983028 | Atacicept | Phase 2 | pMN | Genitourinary | Nov 2027 |
| NCT04716231 | Atacicept | Phase 3 | IgA Nephropathy | Genitourinary | Jul 2028 |
Cash and short-term investments of $384m on 2026-09-30; operating cash outflow about $411m a year; runway about 11 months at that burn, to Sep 2027; 0 of 3 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 13 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Humacyte Prokidney Genexine Vantive Health Cerium Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.